Geminin as an Emerging Anticancer Drug Target

dc.contributor.authorKumar, Shashank
dc.date.accessioned2018-02-19T10:58:10Z
dc.date.accessioned2024-08-13T10:34:24Z
dc.date.available2018-02-19T10:58:10Z
dc.date.available2024-08-13T10:34:24Z
dc.date.issued2016
dc.description.abstractFor normal cell division, one time replication origin firing is mandatory. The mutual interaction and levels of Cdt1 and geminin (GMNN) proteins are known to be involved in this regulatory mechanism. Imbalance between these protein levels may cause defects in replication of DNA leading to genome instability. This might cause cancer. In different stem cells, such as leukemic and hematopoietic stem cells, significant levels of GMNN have been recorded. It has been observed that siRNA mediated GMNN suppression can arrest cancer cell proliferation without affecting the normal cells. Two molecules of GMNN and one molecule of Cdt1 form a heterotrimer, and two heterotrimer combines and form heterohexamer which inhibits the DNA licensing process. Any moiety that is able to inhibit the formation of GMNN-Cdt1 heterohexamer might act as regulatory source and could be utilized as a DNA replication inhibitor in cancer cellsen_US
dc.identifier.citationKushwaha PP, Rapalli KC, Kumar S (2016) Geminin a multi task protein involved in cancer pathophysiology and developmental process: A review. Biochimie 131 (2016) 115-127.en_US
dc.identifier.issn2476-1370
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/598
dc.language.isoenen_US
dc.publisherJuniper Publishersen_US
dc.titleGeminin as an Emerging Anticancer Drug Targeten_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Shashank K 2.pdf
Size:
390.36 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description: